The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

Differential Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on Motor Behavior and Dopamine Levels at Brain Regions in Three Different Mouse Strains

  • Lee, Keun-Sung (Department of Pharmacology, College of Medicine, Dankook University) ;
  • Lee, Jin-Koo (Department of Pharmacology, College of Medicine, Dankook University) ;
  • Kim, Hyung-Gun (Department of Pharmacology, College of Medicine, Dankook University) ;
  • Kim, Hak Rim (Department of Pharmacology, College of Medicine, Dankook University)
  • Received : 2012.12.10
  • Accepted : 2013.01.08
  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Developing an animal model for a specific disease is very important in the understanding of the underlying mechanism of the disease and allows testing of newly developed new drugs before human application. However, which of the plethora of experimental animal species to use in model development can be perplexing. Administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a very well known method to induce the symptoms of Parkinson's disease in mice. But, there is very limited information about the different sensitivities to MPTP among mouse strains. Here, we tested three different mouse strains (C57BL/6, Balb-C, and ICR) as a Parkinsonian model by repeated MPTP injections. In addition to behavioral analysis, endogenous levels of dopamine and tetrahydrobiopterin in mice brain regions, such as striatum, substantia nigra, and hippocampus were directly quantified by liquid chromatography-tandem mass spectrometry. Repeated administrations of MPTP significantly affected the moving distances and rearing frequencies in all three mouse strains. The endogenous dopamine concentrations and expression levels of tyrosine hydroxylase were significantly decreased after the repeated injections, but tetrahydrobiopterin did not change in analyzed brain regions. However, susceptibilities of the mice to MPTP were differed based on the degree of behavioral change, dopamine concentration in brain regions, and expression levels of tyrosine hydroxylase, with C57BL/6 and Balb-C mice being more sensitive to the dopaminergic neuronal toxicity of MPTP than ICR mice.

Keywords

References

  1. Blandini F, Armentero MT. Animal models of Parkinson's disease. FEBS J. 2012;279:1156-1166. https://doi.org/10.1111/j.1742-4658.2012.08491.x
  2. Yokoyama H, Kuroiwa H, Kasahara J, Araki T. Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson's disease. Acta Neurobiol Exp (Wars). 2011;71:269-280.
  3. Prediger RD, Aguiar AS Jr, Moreira EL, Matheus FC, Castro AA, Walz R, De Bem AF, Latini A, Tasca CI, Farina M, Raisman- Vozari R. The intranasal administration of 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease. Curr Pharm Des. 2011;17:489-507. https://doi.org/10.2174/138161211795164095
  4. Onyango IG. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Neurochem Res. 2008;33:589-597. https://doi.org/10.1007/s11064-007-9482-y
  5. Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 2011;164:1357-1391. https://doi.org/10.1111/j.1476-5381.2011.01426.x
  6. Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. J Pharmacol Exp Ther. 1994;270:1000-1007.
  7. Giovanni A, Sonsalla PK, Heikkila RE. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther. 1994;270: 1008-1014.
  8. Ramsay RR, Singer TP. Energy-dependent uptake of N-methyl- 4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem. 1986;261:7585-7587.
  9. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 1985;36:2503-2508. https://doi.org/10.1016/0024-3205(85)90146-8
  10. Mizuno Y, Suzuki K, Sone N, Saitoh T. Inhibition of ATP synthesis by 1-methyl-4-phenylpyridinium ion (MPP+) in isolated mitochondria from mouse brains. Neurosci Lett. 1987;81: 204-208. https://doi.org/10.1016/0304-3940(87)90366-1
  11. Di Monte D, Jewell SA, Ekström G, Sandy MS, Smith MT. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl- 4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. Biochem Biophys Res Commun. 1986;137:310-315. https://doi.org/10.1016/0006-291X(86)91211-8
  12. Volkmann J, Daniels C, Witt K. Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat Rev Neurol. 2010;6:487-498. https://doi.org/10.1038/nrneurol.2010.111
  13. Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, Juncos JL, Obeso JA, Bezard E. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol. 2009;8:1140-1149. https://doi.org/10.1016/S1474-4422(09)70287-X
  14. Duch DS, Smith GK. Biosynthesis and function of tetrahydrobiopterin. J Nutr Biochem. 1991;2:411-423. https://doi.org/10.1016/0955-2863(91)90110-Q
  15. Schmidt TS, Alp NJ. Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin Sci (Lond). 2007;113:47-63. https://doi.org/10.1042/CS20070108
  16. Sonsalla PK, Heikkila RE. Neurotoxic effects of 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:345-354. https://doi.org/10.1016/0278-5846(88)90054-1
  17. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA. 1983;80:4546-4550. https://doi.org/10.1073/pnas.80.14.4546
  18. Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2, 5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 1984;292:390-394. https://doi.org/10.1016/0006-8993(84)90777-7
  19. Antzoulatos E, Jakowec MW, Petzinger GM, Wood RI. Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease. Pharmacol Biochem Behav. 2010;95:466-472 https://doi.org/10.1016/j.pbb.2010.03.009
  20. Kim HR, Kim TH, Hong SH, Kim HG. Direct detection of tetrahydrobiopterin (BH4) and dopamine in rat brain using liquid chromatography coupled electrospray tandem mass spectrometry. Biochem Biophys Res Commun. 2012;419:632-637. https://doi.org/10.1016/j.bbrc.2012.02.064
  21. Kim HR, Graceffa P, Ferron F, Gallant C, Boczkowska M, Dominguez R, Morgan KG. Actin polymerization in differentiated vascular smooth muscle cells requires vasodilator-stimulated phosphoprotein. Am J Physiol Cell Physiol. 2010;298: C559-571. https://doi.org/10.1152/ajpcell.00431.2009
  22. Schwarting RK, Sedelis M, Hofele K, Auburger GW, Huston JP. Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease. Neurotox Res. 1999;1:41-56. https://doi.org/10.1007/BF03033338
  23. Choi HJ, Lee SY, Cho Y, No H, Kim SW, Hwang O. Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: implications for Parkinson's disease. Neurochem Int. 2006;48:255-262. https://doi.org/10.1016/j.neuint.2005.10.011
  24. Ichinose H, Nomura T, Sumi-Ichinose C. Metabolism of tetrahydrobiopterin: its relevance in monoaminergic neurons and neurological disorders. Chem Rec. 2008;8:378-385. https://doi.org/10.1002/tcr.20166
  25. Foxton RH, Land JM, Heales SJ. Tetrahydrobiopterin availability in Parkinson's and Alzheimer's disease; potential pathogenic mechanisms. Neurochem Res. 2007;32:751-756. https://doi.org/10.1007/s11064-006-9201-0
  26. Takazawa C, Fujimoto K, Homma D, Sumi-Ichinose C, Nomura T, Ichinose H, Katoh S. A brain-specific decrease of the tyrosine hydroxylase protein in sepiapterin reductase-null mice--as a mouse model for Parkinson's disease. Biochem Biophys Res Commun. 2008;367:787-792. https://doi.org/10.1016/j.bbrc.2008.01.028
  27. Sundstrom E, Stromberg I, Tsutsumi T, Olson L, Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res. 1987;405:26-38. https://doi.org/10.1016/0006-8993(87)90986-3
  28. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G. Missing pieces in the Parkinson's disease puzzle. Nat Med. 2010;16:653-661. https://doi.org/10.1038/nm.2165
  29. Nagatsu T, Sawada M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. J Neural Transm Suppl. 2006;(71):53-65.
  30. Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiol Dis. 2011;42:327-340. https://doi.org/10.1016/j.nbd.2011.01.024
  31. McMillan PJ, White SS, Franklin A, Greenup JL, Leverenz JB, Raskind MA, Szot P. Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain Res. 2011;1373:240-252. https://doi.org/10.1016/j.brainres.2010.12.015
  32. Kitada T, Tomlinson JJ, Ao HS, Grimes DA, Schlossmacher MG. Considerations regarding the etiology and future treatment of autosomal recessive versus idiopathic Parkinson disease. Curr Treat Options Neurol. 2012;14:230-240. https://doi.org/10.1007/s11940-012-0175-8
  33. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet. 2000;30:171-182. https://doi.org/10.1023/A:1001958023096

Cited by

  1. Neuroprotective Effect of Coptis chinensis in MPP+ and MPTP-Induced Parkinson’s Disease Models vol.44, pp.5, 2013, https://doi.org/10.1142/s0192415x16500506
  2. The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress vol.2016, pp.None, 2013, https://doi.org/10.1155/2016/9730467
  3. Differences in brain regions of three mice strains identified by label-free micro-Raman vol.51, pp.7, 2013, https://doi.org/10.1080/00387010.2018.1473883
  4. Decreased dopamine in striatum and difficult locomotor recovery from MPTP insult after exposure to radiofrequency electromagnetic fields vol.9, pp.None, 2013, https://doi.org/10.1038/s41598-018-37874-z
  5. The Neuroprotective Effects of Astaxanthin: Therapeutic Targets and Clinical Perspective vol.24, pp.14, 2019, https://doi.org/10.3390/molecules24142640
  6. Animal Models for Parkinson’s Disease Research: Trends in the 2000s vol.20, pp.21, 2013, https://doi.org/10.3390/ijms20215402
  7. Fucoxanthin attenuates behavior deficits and neuroinflammatory response in 1-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine-induced parkinson's disease in mice vol.16, pp.67, 2013, https://doi.org/10.4103/pm.pm_318_19
  8. Oxytocin Alleviates MPTP-Induced Neurotoxicity in Mice by Targeting MicroRNA-26a/Death-Associated Protein Kinase 1 Pathway vol.74, pp.3, 2013, https://doi.org/10.3233/jad-191091
  9. Essential Oils as a Potential Neuroprotective Remedy for Age-Related Neurodegenerative Diseases: A Review vol.26, pp.4, 2013, https://doi.org/10.3390/molecules26041107
  10. Impaired mitochondrial functions and energy metabolism in MPTP-induced Parkinson’s disease: comparison of mice strains and dose regimens vol.36, pp.8, 2021, https://doi.org/10.1007/s11011-021-00840-2